Immune Subtypes and Characteristics of Endometrial Cancer Based on Immunogenes

被引:0
作者
Zhang, Chong [1 ]
Xu, Jianqing [1 ]
Wang, Ming [1 ]
He, Yue [1 ]
Wu, Yumei [1 ]
机构
[1] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing Maternal & Child Hlth Care Hosp, Dept Gynecol Oncol, 17 Qihelou St, Beijing 100006, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2024年 / 16卷
关键词
endometrial cancer; immune subtype; immunotherapy; multidimensional genomic; tumor immune microenvironment; GENOMICS; PD-L1;
D O I
10.2147/CMAR.S494838
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this study was to explore the immune subtypes of endometrial cancer (EC) and its characteristics by immunogenes from the perspective of multidimensional genomics (multi-omics).<br /> Patients and Methods: Immune subtypes were carried out using an unsupervised non-negative matrix factorization clustering (NMF) method and their characteristics were analysed. Key genes were identified using random forest analysis. A predictive model for immune subtypes and their clinical prognosis were constructed. The relationship between immune subtypes and molecular subtypes was investigated.<br /> Results: Two immune subtypes C1 and C2 were available. C2 patients were younger, less graded, had significantly higher immune cell infiltration, immune checkpoint expression, tumor neoantigens, tumor mutation load than C1 (P< 005). S100A9, CD3D, CD3E, HLA-DRB1 and IL2RB were the key genes with significant survival outcomes. S100A9 expression was lower in C2 than C1, and IL2RB, HLA-DRB1, CD3E and CD3D expression was higher than C1 (P< 0.05). The predictive accuracy of five key genes for immune subtypes was good, with a Receiver operating characteristic of 0.941. The incidence of TP53abn type in C2 was significantly lower than that of C1, and the incidence of POLE type was significantly higher than that of C1 (P< 0.0001).<br /> Conclusion: EC can be divided into two immune subtypes based on immunogenes. Low expression of S100A9 and high expression of IL2RB, HLA-DRB1, CD3E, and CD3D suggest sensitivity to immunotherapy and a good prognosis.
引用
收藏
页码:1525 / 1543
页数:19
相关论文
共 50 条
  • [11] Carlson Joseph W, 2019, Surg Pathol Clin, V12, P343, DOI 10.1016/j.path.2019.02.003
  • [12] Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
    Charych, Deborah
    Khalili, Samira
    Dixit, Vidula
    Kirk, Peter
    Chang, Thomas
    Langowski, John
    Rubas, Werner
    Doberstein, Stephen K.
    Eldon, Michael
    Hoch, Ute
    Zalevsky, Jonathan
    [J]. PLOS ONE, 2017, 12 (07):
  • [13] S100A8 and S100A9 in Cancer
    Chen, Yu
    Ouyang, Yuzhen
    Li, Zhixin
    Wang, Xiufang
    Ma, Jian
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (03):
  • [14] ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Diagnosis, Treatment and Follow-up
    Colombo, Nicoletta
    Creutzberg, Carien
    Amant, Frederic
    Bosse, Tjalling
    Gonzalez-Martin, Antonio
    Ledermann, Jonathan
    Marth, Christian
    Nout, Remi
    Querleu, Denis
    Mirza, Mansoor Raza
    Sessa, Cristiana
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (01) : 2 - 30
  • [15] Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function
    Dyck, Lydia
    Prendeville, Hannah
    Raverdeau, Mathilde
    Wilk, Mieszko M.
    Loftus, Roisin M.
    Douglas, Aaron
    McCormack, Janet
    Moran, Bruce
    Wilkinson, Michael
    Mills, Evanna L.
    Doughty, Michael
    Fabre, Aurelie
    Heneghan, Helen
    LeRoux, Carel
    Hogan, Andrew
    Chouchani, Edward T.
    O'Shea, Donal
    Brennan, Donal
    Lynch, Lydia
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 219 (03)
  • [16] Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses
    Garber, Ken
    [J]. NATURE BIOTECHNOLOGY, 2018, 36 (05) : 378 - 379
  • [17] Integrated genomic characterization of endometrial carcinoma
    Getz, Gad
    Gabriel, Stacey B.
    Cibulskis, Kristian
    Lander, Eric
    Sivachenko, Andrey
    Sougnez, Carrie
    Lawrence, Mike
    Kandoth, Cyriac
    Dooling, David
    Fulton, Robert
    Fulton, Lucinda
    Kalicki-Veizer, Joelle
    McLellan, Michael D.
    O'Laughlin, Michelle
    Schmidt, Heather
    Wilson, Richard K.
    Ye, Kai
    Ding, Li
    Mardis, Elaine R.
    Ally, Adrian
    Balasundaram, Miruna
    Birol, Inanc
    Butterfield, Yaron S. N.
    Carlsen, Rebecca
    Carter, Candace
    Chu, Andy
    Chuah, Eric
    Chun, Hye-Jung E.
    Dhalla, Noreen
    Guin, Ranabir
    Hirst, Carrie
    Holt, Robert A.
    Jones, Steven J. M.
    Lee, Darlene
    Li, Haiyan I.
    Marra, Marco A.
    Mayo, Michael
    Moore, Richard A.
    Mungall, Andrew J.
    Plettner, Patrick
    Schein, Jacqueline E.
    Sipahimalani, Payal
    Tam, Angela
    Varhol, Richard J.
    Robertson, A. Gordon
    Pashtan, Itai
    Saksena, Gordon
    Onofrio, Robert C.
    Schumacher, Steven E.
    Tabak, Barbara
    [J]. NATURE, 2013, 497 (7447) : 67 - 73
  • [18] Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
    Gulec, Umran Kucukgoz
    Bagir, Emine Kilic
    Paydas, Semra
    Guzel, Ahmet Baris
    Gumurdulu, Derya
    Vardar, Mehmet Ali
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2019, 300 (02) : 377 - 382
  • [19] Identification of a Prognostic Signature for Ovarian Cancer Based on the Microenvironment Genes
    Huo, Xiao
    Sun, Hengzi
    Liu, Shuangwu
    Liang, Bing
    Bai, Huimin
    Wang, Shuzhen
    Li, Shuhong
    [J]. FRONTIERS IN GENETICS, 2021, 12
  • [20] Ji CH, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011790, 10.1097/md.0000000000011790]